Mercury pollution lands two more South Dakota lakes on fish consumption advisory list
State officials have added two more South Dakota lakes to the fish consumption advisory list after testing found elevated mercury levels in large walleye.
The state announced Monday that Dry Lake #1 in Clark County and Lake Henry in Kingsbury County have been added to the list.
For Dry Lake #1, health officials recommend limiting consumption of walleye over 21 inches in length. At Lake Henry, the advisory applies to walleye over 24 inches. Walleye in South Dakota can grow to more than 30 inches.
The guidance is based on mercury concentrations detected in fish tissue samples collected through the state's annual monitoring program.
'Our commitment to public health and safety drives the annual fish sampling program,' said Department of Health Secretary Melissa Magstadt in a news release.
Mercury, a toxic heavy metal, ends up in fish across the United States largely due to atmospheric deposition. Coal-fired power plants release mercury into the air before it settles into lakes and rivers. Bacteria convert it into methylmercury and fish absorb it.
Fish consumption advisories are not enforceable bans but are issued to help people make informed choices to reduce health risks.
'We encourage everyone to check the DOH website for the latest advisories and take necessary precautions when enjoying locally caught fish,' Magstadt said.
In addition to Dry Lake #1 and Lake Henry, these lakes are on the state's fish consumption advisory list:
Bitter Lake: Limit consumption of northern pike (over 30″) and any size walleye, particularly for children under age 7 and women who are pregnant, might become pregnant, or are breastfeeding.
Coal Springs Reservoir: Limit consumption of northern pike (over 25″). These tested above recommended limits for mercury.
Cottonwood Lake: Limit consumption of walleye (over 21″). These tested above recommended limits for mercury.
Dry Lake Number 2: Limit consumption of walleye (over 22″). These tested above recommended limits for mercury.
Elm Lake: Limit consumption of walleye (over 25″). These tested above recommended limits for mercury.
Hazeldon Lake: Limit consumption of walleye (over 21″). These tested above recommended limits for mercury.
Horseshoe Lake: Limit consumption of walleye (over 18″). These tested above recommended limits for mercury.
Kiesz Lake: Limit consumption of walleye (over 16″). These tested above recommended limits for mercury.
Lake Hurley: Limit consumption of Largemouth Bass (over 18″). These tested above recommended limits for mercury.
Lake Isabel: Limit consumption of northern pike (over 25″) and Largemouth Bass (over 17″). These tested above recommended limits for mercury.
Lake Minnewasta: Limit consumption of walleye (over 18″). These tested above recommended limits for mercury.
Lardy Lake: Limit consumption of walleye (over 18″). These tested above recommended limits for mercury.
Little Moreau Lake: Limit consumption of northern pike (over 26″). These tested above recommended limits for mercury.
Long Lake: Limit consumption of walleye (over 17″). These tested above recommended limits for mercury.
Lynn Lake: Limit consumption of walleye (over 25″). These tested above recommended limits for mercury.
Middle Lynn Lake: Limit consumption of walleye (over 18″). These tested above recommended limits for mercury.
New Wall Lake: Limit consumption of black and white crappie (over 13″) and Largemouth Bass (over 16″). These tested above recommended limits for mercury.
Newell Lake: Limit consumption of walleye (over 18″) and northern pike (over 18″). These tested above recommended limits for mercury.
North Buffalo Lake: Limit consumption of walleye (over 21″). These tested above recommended limits for mercury.
North Island Lake: Limit consumption of walleye (over 18″) and Smallmouth Bass (over 19″). These tested above recommended limits for mercury.
Opitz Lake: Limit consumption of northern pike (over 26″). These tested above recommended limits for mercury.
Pickerel Lake: Limit consumption of white bass (over 16'), particularly for children under age 7 and women who are pregnant, might become pregnant, or are breastfeeding.
Pudwell Dam: Limit consumption of walleye (over 18″) and Black Crappie (over 12″). These tested above recommended limits for mercury.
Reid Lake: Limit consumption of walleye (over 23″) and northern pike (over 32″). These tested above recommended limits for mercury.
Roosevelt Lake: Limit consumption of largemouth bass (over 18″) and northern pike (over 24″). These tested above recommended limits for mercury.
Scott Lake: Limit consumption of walleye (over 25″). These tested above recommended limits for mercury.
South Buffalo Lake: Limit consumption of walleye (over 21″). These tested above recommended limits for mercury.
Swan Lake: Limit consumption of walleye (over 21″). These tested above recommended limits for mercury.
Twin Lakes (Minnehaha County): Limit consumption of any size walleye, particularly for children under age 7 and women who are pregnant, might become pregnant, or are breastfeeding. Walleye tested above recommended limits for mercury.
Twin Lakes (Brookings/Kingsbury counties): Limit consumption of walleye (over 18″) and northern pike (over 19″). These tested above recommended limits for mercury.
Source: South Dakota Department of Health
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
18 hours ago
- CBS News
Measles case confirmed in Passaic County, New Jersey, health officials say
A case of measles has been confirmed in Passaic County, New Jersey, health officials announced Saturday. According to the state Department of Health, the patient recently traveled internationally, and this case is not related to measles cases in Hudson and Ocean counties that were reported in July. Health officials say the patient visited the Chilton Medical Center in Pompton Plains while contagious. Anyone who was in the emergency department between 7 p.m. on July 31 and 3:30 a.m. on Aug. 1 or the main hospital's fifth floor Intensive Care Unit between 1:30 a.m. and 12:30 p.m. on Aug. 1 may have been exposed to measles. Anyone who was exposed at those times could develop symptoms as late as Aug. 24, if infected. This is the sixth case of measles in New Jersey so far this year. Measles is spread when an infected person coughs or sneezes and can remain in the air for up to two hours. It can also be spread through an infected person's mucus or saliva. According to health officials, measles symptoms include high fever, cough, runny nose, watery red eyes, and a rash that appears as flat red spots on the face and all over the body. Anyone who suspects they have or were exposed to measles should call their local health department or health care provider to make special arrangements for evaluation. Potential patients are urged to call ahead before arriving at a medical office or emergency department due to the risk of infecting other visitors and medical staff. Those who have not received both doses of the MMR vaccine or had measles in the past are most at risk of becoming infected. All New Jersey residents are encouraged to stay up to date on vaccinations, and anyone travelling internationally should be fully vaccinated before leaving the country, the health department says. Data released by the Centers for Disease Control and Prevention in July shows 2025 is the worst year for measles in the United States since 1992. There have been 14 measles cases in New York so far this year, according to the latest state health department data. That includes seven cases in New York City, four cases in Orange County, one in Putnam County, one in Suffolk County and one in Ontario County. There have not been any cases of measles in Connecticut so far this year.
Forbes
2 days ago
- Forbes
A Regulated Trip: What New Mexico's Psilocybin Law Means For Work
Magic mushrooms are now medicine in New Mexico. And that shift could have ripple effects in the workplace. This spring, Governor Michelle Lujan Grisham signed Senate Bill 219, the Medical Psilocybin Act, into law, making New Mexico the third state to legalize psilocybin for medical use. Unlike Oregon and Colorado, which adopted their psilocybin programs through ballot initiatives, New Mexico enacted its law through the legislative process. That distinction is more than procedural. It reflects an institutional shift toward integrating psychedelic therapy into the framework of state-managed healthcare. The law took effect on June 20, 2025, and requires full program implementation by December 31, 2027. With that, New Mexico becomes the first state to create a clinician-administered psilocybin program governed by medical oversight, not consumer access. As psilocybin therapy enters a regulated medical model, employers must now examine how psilocybin intersects with workplace safety, disability accommodation, and drug policy enforcement. Psilocybin's Reintroduction as Medicine Psilocybin is a naturally occurring psychedelic compound found in certain mushrooms. Once ingested, it metabolizes into psilocin, which affects cognition, mood, and perception. Although it remains a Schedule I substance under federal law, psilocybin has reemerged over the past decade as a potential breakthrough therapy for severe mental health conditions. Peer-reviewed research continues to highlight its therapeutic potential in treating major depression, PTSD, substance use disorders, and end-of-life distress. New Mexico's legislation embraces this emerging science by establishing a medical-use program in which licensed clinicians, not dispensaries, administer psilocybin in approved therapeutic settings. The Department of Health is responsible for creating treatment protocols, licensing standards, clinician training, and oversight mechanisms. The Act also establishes both a research fund and a treatment equity fund to expand access and support clinical study. Psychedelic wellness expert Cesar Marin sees the program as a reflection of how far public understanding has evolved. 'We're not talking about the free‑wheeling psychedelic trips of the 1960s anymore,' Marin says. 'We're seeing most states consider or enact some form of psychedelic policy reform, and that momentum helps people feel more comfortable with the intentional, therapeutic use of psilocybin.' Qualifying conditions are narrowly defined to include treatment-resistant depression, PTSD, substance use disorder, and terminal illness. All treatment must occur in controlled environments with preparatory and integration sessions surrounding the administration of psilocybin. Psilocybin and psilocin are removed from the state's list of Schedule I controlled substances when used in accordance with the law, and services provided under the Act are exempt from New Mexico's gross receipts tax. Legal Protections Without Workplace Requirements The Medical Psilocybin Act offers strong protections for individuals operating within its boundaries. Licensed clinicians, producers, and qualified patients cannot be prosecuted under state law, and individuals on probation or awaiting trial may participate in treatment without jeopardizing their legal status. However, the Act stops short of granting any employment-based rights. It does not require employers to accommodate psilocybin use, nor does it prevent adverse action based on lawful participation in the program. That omission is deliberate and significant. While patients may legally participate in psilocybin-assisted therapy under state law, the federal classification of psilocybin as a Schedule I substance remains unchanged. And unlike medical cannabis laws in some states, New Mexico's psilocybin law provides no employment protections, no retaliation standard, and no accommodation framework. Still, employers should not assume the workplace will remain untouched. A New Compliance Challenge for Employers 'New Mexico legalizing medical psilocybin is a huge step toward bringing these treatments out of the shadows and into mainstream medicine,' says Marin. 'When folks see local leaders endorsing these programs, it lowers the fear factor and makes it easier for someone who's curious to explore them.' That shift in perception could soon reach the workplace. Employers may begin receiving accommodation requests from individuals participating in medically supervised psilocybin therapy for conditions like PTSD, treatment-resistant depression, or substance use disorder. And while psilocybin remains a federally controlled substance, the conditions it treats are often considered disabilities under the Americans with Disabilities Act (ADA). That means employers have a legal obligation to engage in the interactive process when an employee discloses a disability and requests accommodation, even if the employee's treatment involves a Schedule I substance like psilocybin. The ADA does not require employers to accommodate federally illegal drug use, but it does require them to consider accommodations related to the underlying condition. Employers are not obligated to tolerate on-the-job impairment or excuse safety violations. Still, if an employee reports off-duty participation in a licensed psilocybin program tied to a recognized condition, a flat denial without further inquiry could invite scrutiny under disability discrimination laws. Testing vs. Impairment: Where Policy Meets Practicality Psilocybin presents unique challenges when it comes to workplace drug testing. Unlike THC or opioids, psilocin, the active compound after ingestion, is not included in most standard employment drug panels. That means employers may be flying blind when it comes to detecting recent psilocybin use unless they specifically request an expanded panel. 'A person can be actively hallucinating due to psilocybin use and still pass a standard workplace drug test,' says Dr. Todd Simo, Chief Medical Officer at HireRight. 'Psilocin, the active compound, doesn't show up in most drug panels unless an employer specifically includes it. That's why training managers to recognize signs of impairment and providing a clear path to escalate reasonable suspicion are more effective strategies. For employers especially concerned, developing a reasonable suspicion panel that includes psilocybin and disclosing it to employees in advance can also help mitigate misuse.' Given that reality, employers may want to prioritize impairment-based enforcement strategies over reliance on traditional drug screening. While testing has its place, especially in post-accident investigations or in regulated industries, training supervisors to recognize signs of real-time impairment and respond consistently under internal policy is likely a more practical approach for most workplaces. Preparing for Disclosure and Dialogue Employers should take this opportunity to review and, where necessary, revise internal policies addressing drug and alcohol use, workplace impairment, and reasonable accommodations. Clarity around off-duty substance use and on-duty safety expectations will be essential. HR teams should also ensure that accommodation request procedures are equipped to handle emerging treatment disclosures, particularly where mental health conditions are involved. Equally important is creating an environment in which employees feel safe discussing mental health. Psilocybin's path to medical legitimacy mirrors, in many ways, the evolution of medical cannabis and broader mental health parity. For employers, staying ahead of these developments will require not only legal awareness but organizational empathy. The Bigger Picture New Mexico's Medical Psilocybin Act signals more than therapeutic access. It reflects a policy evolution, one where lawmakers, not just voters, are beginning to treat psychedelic medicine as a legitimate part of behavioral healthcare. The state's approach shifts the narrative from stigma to structure, putting psilocybin in the hands of trained clinicians operating under medical oversight. And while the law places no new obligations on employers, it surfaces a timely question: what does it mean to support mental health in a world where the frontier of treatment is changing? For employers, that shift invites action. It's time to revisit drug policies, reconsider testing strategies, and refine accommodation practices. As state-level momentum builds around psychedelics, employers don't need to endorse these therapies, but they do need to understand them. Because in the modern workplace, curiosity can be a better compliance strategy than surprise.
Business Upturn
2 days ago
- Business Upturn
P&G Health shares surge 8% as Q1 revenue jumps 19.5% YoY to Rs 339 crore
Shares of Procter & Gamble Health surged over 8% on Friday following the company's robust financial performance in the first quarter of FY26. The stock touched a high of ₹6,476, rising sharply from the previous close of ₹5,895.50. As of 2:12 PM, the shares were trading 7.97% higher at Rs 6,365.50. P&G Health reported a massive jump in net profit, which stood at ₹66.2 crore, up from ₹16.8 crore in the same quarter last year. Revenue for the quarter rose 19.5% year-on-year to ₹339 crore, compared to ₹283.8 crore in Q1FY25. The company's EBITDA also witnessed strong growth, rising 89% to ₹90.5 crore from ₹48.2 crore last year. Operating margins expanded to 26.7%, a significant improvement from 17% in the year-ago period. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
